TOP 1288

Drug Profile

TOP 1288

Alternative Names: TOP-1288

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TopiVert
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunomodulators; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis

Most Recent Events

  • 08 Jan 2018 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Ulcerative colitis released by TopiVert Pharma (PO)
  • 28 Jun 2017 AbbVie completes a phase II trial in Ulcerative colitis in Hungary, Latvia, Lithuania, Poland, United Kingdom, Czech Republic, Bulgaria and Ukraine (Rectal) (NCT02888379)
  • 02 Jun 2017 Topivert Pharma completes a phase I trial in Ulcerative colitis (In volunteers) in United Kingdom (PO) (NCT03071081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top